Neo-ALTTO trial is now closed to enrollment
The Neo-ALTTO trial is a companion trial to ALTTO that evaluates the effectiveness of lapatinib (Tykerb®/Tyverb®) as neoadjuvant therapy for HER2 (ErbB2)-positive breast cancer.

The Neo-ALTTO trial explores whether treatment with lapatinib, trastuzumab (Herceptin®), or their combination, together with a traditional chemotherapy (paclitaxel), can reduce the size of breast tumours prior to surgery. In addition, future translational studies will help to identify biomarkers of sensitivity or resistance to these agents.

This global trial recruited 455 women with HER2-positive breast cancer at about 130 sites (hospitals or doctor's offices) in approximately 30 countries. Patients will receive anti-HER2 study treatments for a total of 1 year (18 weeks presurgery, and 34 weeks postsurgery). The trial is now closed to enrollment (the last patient was randomised in December 2009).

Neo-ALTTO is organised by BIG (Breast International Group) and the Spanish-based SOLTI (SOLid Tumour Intensification) Group. Neo-ALTTO is also conducted in collaboration with GlaxoSmithKline.

For information about ALTTO, a companion trial evaluating lapatinib in women who have had surgery to remove a breast cancer tumour, click on the ALTTO button at left. The ALTTO trial is now closed to enrolment.

Translational Research Proposals
Researchers in the scientific community may apply for use of biological materials collected during the Neo-ALTTO trial to conduct translational research. Prior affiliation with the ALTTO trials is not required. Proposals are now being accepted. Please refer to the information and forms below.

NEW: Third call for Neo-ALTTO Research Proposals. Proposals using serum/plasma samples to be submitted by 1 October 2012.

Tykerb and Tyverb are registered trade marks of the GlaxoSmithKline group of companies.
Herceptin is a registered trade mark of Genentech, Inc.

Copyright © 2012 GlaxoSmithKline Group of Companies
All rights reserved.